Markers of radioresistance in squamous cell carcinomas of the head and neck: A clinicopathologic and immunohistochemical study

Journal of Clinical Oncology

Volumn 15, Issue 3, 1997, Pages 1030-1038

  Raybaud Diogene H ^a   Fortin, A ^a   Morency, R ^a   Roy, J ^a   Monteil, R A ^a   Tetu B ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; TUMOR MARKER;

ADVANCED CANCER; ARTICLE; CANCER STAGING; CELL PROLIFERATION; DIAGNOSTIC ACCURACY; GENE EXPRESSION; HEAD AND NECK CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RADIOSENSITIVITY; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY; TUMOR GROWTH;

EID: 0031059355     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.3.1030     Document Type: Article

References (55)

1. Vokes EE, Weichselbaum RR, Lippman SM, et al: Head and neck cancer. N Engl J Med 328:184-194, 1993
2. Peters LJ, Brock WA, Chapman JD, et al: Predictive assays of tumor radiocurability. Am J Clin Oncol 11:275-287, 1988
3. Nair MK, Sankaranarayanan R, Krihnan E, et al: Independent predictors of response and disease-free survival in oral cancer treated with radical radiation therapy. Cancer 69:2221-2226, 1992
4. Hall EJ: Predictive assays, in Hall EJ (ed): Radiobiology for the Radiobiologist. Philadelphia, PA, Lippincott, 1994, pp 245-256
5. Weichselbaum RR, Beckett MA, Hallahan DE, et al: Molecular targets to overcome radioresistance. Semin Oncol 19:14-20, 1992
6. Withers RH, Peters LJ, Taylor JMG, et al: Local control of carcinoma of the tonsil by radiation therapy: An analysis of patterns of fractionation in nine institutions. Int J Radiat Oncol Biol Phys 33:549-562, 1995
7. Lee JM, Bernstein A: p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA 90:5742-5746, 1993
8. Lowe SW, Bodis S, McClatchey A, et al: p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810, 1994
9. Willen CG, Warland G, Hagan MP, et al: Tumor proliferation in rectal cancer following preoperative irradiation. J Clin Oncol 13:1417-1424, 1995
10. Têtu B, Brisson J: Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer: The influence of the pattern of immunostaining and adjuvant therapy. Cancer 73:2359-2365, 1994
11. Huot J, Roy G, Lambert H, et al: Increased survival after treatments with anticancer agents of Chinese hamster cells expressing the human M 27,000 heat shock protein. Cancer Res 51:5245-5252, 1991
12. Raybaud-Diogène H, Morency R, Têtu B, et al: p53 overexpression in head and neck squamous cell carcinoma: Review of literature. Eur J Cancer 32B:143-145, 1996
13. Field JK, Pavelic ZP, Spandidos DA, et al: The role of the p53 tumor suppressor gene in squamous cell carcinoma of head and neck. Arch Otolaryngol Head Neck Surg 119:1118-1122, 1993a
14. Field JK, Malliri A, Butt SA: p53 overexpression in end stage squamous cell carcinoma of the head and neck: Correlates with a very poor clinical out-come. Int J Oncol 3:431-435, 1993b
15. Lane DP, Benchimol S: p53: Oncogene or anti-oncogene? Genes Dev 4:1-8, 1990
16. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 351:453-456, 1991
17. Chang F, Syrjänen S, Syrjänen K: Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 13:1009-1022, 1995
18. Maity A, McKenna WG, Muschel RJ: The molecular basis for cell cycle delays following ionizing radiation: A review. Radiother Oncol 31:1-13, 1994
19. Lynch DAF, Clarke AMT, Jackson P, et al: Comparison of labelling by bromodeoxyuridine, MIB-1, and proliferating cell nuclear antigen in gastric mucosal biopsy specimens. J Clin Pathol 47:122-125, 1994
20. Maguire HC Jr, Greene MI: The neu (c-erbB-2) oncogene. Semin Oncol 16:148-155, 1989
21. Hou L, Shi D, Tu SM, et al: Oral cancer progression and c-erbB-2/neu protooncogene expression. Cancer Lett 65:215-220, 1992
22. Landry J, Chrétien P, Lambert H, et al: Heat shock resistance conferred by expression of the human HSP-27 gene on rodent cells. J Cell Biol 109:7-15, 1989
23. Terrier P, Townsend AJ, Coindre JM, et al: An immunohistochemical study of pi class glutathione S transferase expression in normal human tissue. Am J Pathol 137:845-853, 1990
24. Schecter RL, Alaoui-Jamali MA, Batist G: Glutathione S-transferase in chemotherapy resistance and carcinogenesis. Biochem Cell Biol 70:349-353, 1992
25. Ozols RF, Masuda H, Hamilton TC: Keynote address: Mechanisms of cross-resistance between radiation and antineoplastic drugs. NCI Monogr 6:159-165, 1988
26. Mulder TPJ, Manni JJ, Roelofs HMJ, et al: Glutathione S-transferases and glutathione in human head and neck cancer. Carcinogenesis 16:619-624, 1995
27. Hsu SM, Raine L, Fanger H: Use of the avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29:577-580, 1981
28. Christensen E: Multivariate survival analysis using Cox's regression model. Hepatology 7:1346-1358, 1987
29. Hill C, Com-Nougué C, Kramar A, et al: Analyse statistique des données de survie. Paris, France, Flammarion, 1990
30. Bouyer J, Hémon D, Cordier S, et al: Épidémiologie principes et méthodes quantitatives. Paris, France, Les éditions INSERM, 1993
31. Simon R, Altman DG: Statistical aspects of prognostic factor studies in oncology. Br J Cancer 69:979-985, 1994
32. Clark GM: Prognostic and predictive factors, in Harris JR, Lippman ME, Morrow M, et al (eds): Diseases of the Breast. Philadelphia, PA, Lippincott Raven, 1996, pp 469-485
33. Stal O, Askmalm MS, Wingren S, et al: p53 expression and the result of adjuvant therapy of breast cancer. Acta Oncol 34:767-770, 1995
34. Lane PD: p53, guardian of the genome. Nature 358:15-16, 1992
35. Murnane JP: Cell cycle regulation in response to DNA damage in mammalian cells: A historical perspective. Cancer Metastasis Rev 14:17-29, 1995
36. Greenblatt MS, Bennett WP, Hollstein M, et al: Mutations in p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878, 1994
37. Wilson GD, Richman PI, Dische S, et al: p53 status of head and neck cancer: Relation to biological characteristics and outcome of radiotherapy. Br J Cancer 71:1248-1252, 1995
38. Allred DC, Clark GM, Elledge R, et al: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85:200-206, 1993
39. Marchetti A, Buttitta F, Pellegrini S, et al: p53 mutations and histological type of invasive breast carcinoma. Cancer Res 53:4665-4669, 1993
40. Drobnjak M, Latres E, Pollack D, et al: Prognostic implications of p53 nuclear overexpression and high proliferation index of Ki-67 in adult soft tissue sarcomas. J Natl Cancer Inst 86:549-554, 1994
41. Warnakulasuriya KAAS, Johnson NW: Association of overexpression of p53 oncoprotein with the state of cell proliferation in oral carcinoma. J Oral Pathol Med 23:246-250, 1994
42. Fontanini G, Bigini D, Vignati S, et al: p53 expression in non small cell lung cancer: Clinical and biological correlations. Anticancer Res 13:737-742, 1993
43. Potten CS: A comprehensive review of the radiobiologic response of the murine (BDF1) small intestine - A review. Int J Radiat Biol 58:925-973, 1990
44. Milas L, Hunter N, Peters LJ: The tumor bed effect: Dependence of tumor uptake, growth rate, and metastasis on the time interval between irradiation and tumor cell transplantation. Int J Radiat Oncol Biol Phys 13:379-383, 1987
45. Valente G, Orecchia R, Gandolfo S, et al: Can Ki67 immunostaining predict response to radiotherapy in oral squamous cell carcinoma? J Clin Pathol 47:109-112, 1994
46. Nakano T, Oka K: Differential values of Ki-67 index and mitotic index of proliferating cell population. An assessment of cell cycle and prognosis in radiation therapy for cervical cancer. Cancer 72:2401-2408, 1993
47. Swanson SA, Brooks JJ: Proliferation markers Ki-67 and p105 in soft tissue lesions. Correlation with DNA flow cytometric characteristics. Am J Pathol 137:1491-1500, 1990
48. Kubota Y, Petras RE, Easley KA, et al: Ki-67 determined growth fraction versus standard staging and grading parameters in colorectal carcinoma. A multivariate analysis. Cancer 70:2602-2609, 1992
49. Veronese SM, Gambacorta M, Gottardi O, et al: Proliferation index as a prognostic marker in breast cancer. Cancer 71:3926-3931, 1993
50. Harpole DH Jr, Herndon JE II, Wolfe WG, et al: A prognostic model of recurrence and death in stage I non small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 55:51-56, 1995
51. Ahomadegbe JC, Barrois M, Fogel S, et al: High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non invasive lesions. Oncogene 10:1217-1227, 1995
52. Resnick JM, Uhlman D, Niehans GA, et al: Cervical lymph node status and survival in laryngeal carcinoma: Prognostic factors. Ann Otol Rhinol Laryngol 104:685-694, 1995
53. Ebina M, Steinberg SM, Mulshine JL, et al: Relationship of p53 overexpression and up regulation of proliferating cell nuclear antigen with the clinical course of non-small-cell lung cancer. Cancer Res 54:2496-2503, 1994
54. Isola J, Visakorpi T, Holli K, et al: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84:1109-1114, 1992
55. Liu TJ, El-Naggar AK, McDonnell TJ, et al: Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res 55:3117-3122, 1995